Aripiprazole (Page 4 of 16)
Dyslipidemia
Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.
There were no significant differences between aripiprazole- and placebo-treated patients in the proportion with changes from normal to clinically significant levels for fasting/nonfasting total cholesterol, fasting triglycerides, fasting LDLs, and fasting/nonfasting HDLs. Analyses of patients with at least 12 or 24 weeks of exposure were limited by small numbers of patients.
Adults
Table 5 shows the proportion of adult patients, primarily from pooled schizophrenia and bipolar disorder monotherapy placebo-controlled trials, with changes in total cholesterol (pooled from 17 trials; median exposure 21 to 25 days), fasting triglycerides (pooled from eight trials; median exposure 42 days), fasting LDL cholesterol (pooled from eight trials; median exposure 39 to 45 days, except for placebo-treated patients with baseline normal fasting LDL measurements, who had median treatment exposure of 24 days) and HDL cholesterol (pooled from nine trials; median exposure 40 to 42 days).‑‑
Treatment Arm | n/N | % | |
---|---|---|---|
Total Cholesterol | |||
Normal to High | Aripiprazole | 34/1357 | 2.5 |
(<200 mg/dL to ≥240/mg/dL) | Placebo | 27/973 | 2.8 |
Fasting Triglycerides | |||
Normal to High | Aripiprazole | 40/539 | 7.4 |
(<150 mg/dL to ≥200 mg/dL) | Placebo | 30/431 | 7.0 |
Fasting LDL Cholesterol | |||
Normal to High | Aripiprazole | 2/332 | 0.6 |
(<100 mg/dL to ≥160 mg/dL) | Placebo | 2/268 | 0.7 |
HDL Cholesterol | |||
Normal to Low | Aripiprazole | 121/1066 | 11.4 |
(≥40 mg/dL to <40 mg/dL) | Placebo | 99/794 | 12.5 |
In monotherapy trials in adults, the proportion of patients at 12 weeks and 24 weeks with changes from Normal to High in total cholesterol (fasting/nonfasting), fasting triglycerides, and fasting LDL cholesterol were similar between aripiprazole- and placebo-treated patients: at 12 weeks, Total Cholesterol (fasting/nonfasting), 1/71 (1.4%) vs. 3/74 (4.1%); Fasting Triglycerides, 8/62 (12.9%) vs. 5/37 (13.5%); Fasting LDL Cholesterol, 0/34 (0%) vs. 1/25 (4.0%), respectively; and at 24 weeks, Total Cholesterol (fasting/nonfasting), 1/42 (2.4%) vs. 3/37 (8.1%); Fasting Triglycerides, 5/34 (14.7%) vs. 5/20 (25%); Fasting LDL Cholesterol, 0/22 (0%) vs. 1/18 (5.6%), respectively.
‑‑Pediatric Patients and Adolescents
Table 6 shows the proportion of adolescents with schizophrenia (13 to 17 years) and pediatric patients with bipolar disorder (10 to 17 years) with changes in total cholesterol and HDL cholesterol (pooled from two placebo-controlled trials; median exposure 42 to 43 days) and fasting triglycerides (pooled from two placebo-controlled trials; median exposure 42 to 44 days).
Table 6: Changes in Blood Lipid Parameters From Placebo-Controlled Monotherapy Trials in Pediatric and Adolescent Patients in Schizophrenia and Bipolar Disorder
Treatment Arm | n/N | % | |
---|---|---|---|
Total Cholesterol | |||
Normal to High | Aripiprazole | 3/220 | 1.4 |
(<170 mg/dL to ≥200/mg/dL) | Placebo | 0/116 | 0 |
Fasting Triglycerides | |||
Normal to High | Aripiprazole | 7/187 | 3.7 |
(<150 mg/dL to ≥200 mg/dL) | Placebo | 4/85 | 4.7 |
HDL Cholesterol | |||
Normal to Low | Aripiprazole | 27/236 | 11.4 |
(≥40 mg/dL to <40 mg/dL) | Placebo | 22/109 | 20.2 |
‑‑In monotherapy trials of adolescents with schizophrenia and pediatric patients with bipolar disorder, the proportion of patients at 12 weeks and 24 weeks with changes from Normal to High in total cholesterol (fasting/nonfasting), fasting triglycerides, and fasting LDL cholesterol were similar between aripiprazole- and placebo-treated patients: at 12 weeks, Total Cholesterol (fasting/nonfasting), 0/57 (0%) vs. 0/15 (0%); Fasting Triglycerides, 2/72 (2.8%) vs. 1/14 (7.1%), respectively; and at 24 weeks, Total Cholesterol (fasting/nonfasting), 0/36 (0%) vs. 0/12 (0%); Fasting Triglycerides, 1/47 (2.1%) vs. 1/10 (10.0%), respectively.
Weight Gain
Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.
Adults
In an analysis of 13 placebo-controlled monotherapy trials, primarily from pooled schizophrenia and bipolar disorder, with a median exposure of 21 to 25 days, the mean change in body weight in aripiprazole-treated patients was +0.3 kg (N=1673) compared to –0.1 kg (N=1100) in placebo-controlled patients. At 24 weeks, the mean change from baseline in body weight in aripiprazole-treated patients was –1.5 kg (n=73) compared to –0.2 kg (n=46) in placebo-treated patients.
Table 7 shows the percentage of adult patients with weight gain ≥7% of body weight by indication.
Indication | Treatment Arm | N | Patients n (%) | |
Schizophreniaa | Aripiprazole | 852 | 69 (8.1) | |
Weight Gain | Placebo | 379 | 12 (3.2) | |
≥7% of | Bipolar Maniab | Aripiprazole | 719 | 16 (2.2) |
body weight | Placebo | 598 | 16 (2.7) |
a 4-6 weeks duration. b 3 weeks duration.
‑‑Pediatric Patients and Adolescents
In an analysis of two placebo-controlled trials in adolescents with schizophrenia (13 to 17 years) and pediatric patients with bipolar disorder (10 to 17 years) with median exposure of 42 to 43 days, the mean change in body weight in aripiprazole-treated patients was +1.6 kg (N=381) compared to +0.3 kg (N=187) in placebo-treated patients. At 24 weeks, the mean change from baseline in body weight in aripiprazole-treated patients was +5.8 kg (n=62) compared to +1.4 kg (n=13) in placebo-treated patients.
Table 8 shows the percentage of pediatric and adolescent patients with weight gain ≥7% of body weight by indication.
| ||||
Indication | TreatmentArm | N | Patientsn (%) | |
Weight gain ≥7% | Pooled Schizophrenia | Aripiprazole | 381 | 20 (5.2) |
of body weight | and Bipolar Mania * | Placebo | 187 | 3 (1.6) |
‑‑In an open-label trial that enrolled patients from the two placebo-controlled trials of adolescents with schizophrenia (13 to 17 years) and pediatric patients with bipolar disorder (10 to 17 years), 73.2% of patients (238/325) completed 26 weeks of therapy with aripiprazole. After 26 weeks, 32.8% of patients gained ≥7% of their body weight, not adjusted for normal growth. To adjust for normal growth, z-scores were derived (measured in standard deviations [SD]), which normalize for the natural growth of pediatric patients and adolescents by comparisons to age- and gender-matched population standards. A z-score change <0.5 SD is considered not clinically significant. After 26 weeks, the mean change in z-score was 0.09 SD.
When treating pediatric patients for any indication, weight gain should be monitored and assessed against that expected for normal growth.
Additonal pediatric use information is approved for Otsuka America Pharmaceutical, Inc.’s ABILIFY® (aripiprazole) product. However, due to Otsuka America Pharmaceutical, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.